Lung Cancer Screen Test - EarlyCDT®

A simple Lung Cancer Screen blood test designed to help assess lung cancer risk earlier

The EarlyCDT® Lung Cancer Blood Test is a clinically developed blood test that detects specific autoantibodies associated with lung cancer. These autoantibodies can appear in the blood months or even years before symptoms develop, offering the opportunity for earlier clinical assessment.

This test is intended for individuals who may be at increased risk of lung cancer, including current or former smokers, or those with a relevant personal or occupational exposure history.

How the test works

Cancer cells can trigger the immune system to produce autoantibodies at very early stages of disease development. The EarlyCDT® Lung test looks for a specific panel of these autoantibodies using a single blood sample.

Key benefits

• Simple blood test – requires only a standard blood draw

• Early risk insight – may detect immune responses associated with lung cancer before symptoms appear

• Clinically validated technology – backed by peer-reviewed research

• Non-invasive – no scans or imaging required at the testing stage

• Supports clinical decision-making – results can be shared with your healthcare professional

Who may consider this test?

• Current or former smokers

• Individuals aged 40+ with increased lung cancer risk factors

• Those seeking additional information to support discussions with their clinician